

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 40130

**Title:** CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy

**Reviewer's code:** 00503623

**Reviewer's country:** United States

**Science editor:** Jin-Lei Wang

**Date sent for review:** 2018-06-10

**Date reviewed:** 2018-06-18

**Review time:** 8 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

This manuscript reports the results of studies on the impact of cytochrome P450C2 and IL-1 polymorphism on the efficacy of Hp eradication by using rabeprazole-based therapy. The results obtained with 88 patients revealed that the P450C2 and IL-1 polymorphism is not affect significantly the rate of Hp eradication by rabeprazole-based



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

hybrid therapy. Hence, the conclusion is that CYP2C19 and IL-1b polymorphism do no impact significantly the outcome of rabeprazole-based therapy. The study is well presented, clearly written, and should be interest to the readership.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 40130

**Title:** CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy

**Reviewer's code:** 02441154

**Reviewer's country:** Taiwan

**Science editor:** Jin-Lei Wang

**Date sent for review:** 2018-06-10

**Date reviewed:** 2018-07-01

**Review time:** 20 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

The aim of this study was to investigate the impacts of CYP2C19 and IL-1 $\beta$  polymorphisms on the efficacy of hybrid therapy for H pylori infection. My specific comments are as follows: Comment 1. P5, Introduction, line 12: Please mention the major findings of previous studies investigating the impact of IL-1 $\beta$  genetic polymorphism on



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

the eradication rates of other anti-H pylori therapies (e.g., J Gastroenterol Hepatol 2009;24:1725-32; Am J Gastroenterol. 2003;98:2403-8). In addition, please point out that this study is the pilot work investigating the impact of IL-1 $\beta$  genetic polymorphism on the eradication rate of hybrid therapy Comment 2. P6, Methods, line 12: The exclusion criteria included “use of concomitant medication”. Were patients receiving medication for hypertension, diabetes or coronary artery disease also excluded from this study? Comment 3. P19, Results, Table 2: Table 2 was too complicated and should be revised. The authors can delete the second column and second row. In addition, please also analyze the impact of IL-1 $\beta$  genetic polymorphism on the eradication rate of patients with EM genotype and the impact of IL-1 $\beta$  genetic polymorphism on the eradication rate of patients with non-EM genotype in the table. Comment 4. P10, Results: How about the impacts of antibiotic resistances on the eradication efficacy of hybrid therapy in this study? Comment 5. P13, Discussion: Please discuss the limitations of the study in the Discussion section. In my opinion, the number of cases in this study was relatively small to identify some minor factors predicting eradication failure.

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

### *BPG Search:*

- ☐ The same title
- ☐ Duplicate publication



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA

**Telephone:** +1-925-223-8242

**Fax:** +1-925-223-8243

**E-mail:** bpgoffice@wjgnet.com

**https://**www.wjgnet.com

[ ] Plagiarism

[ Y ] No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 40130

**Title:** CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy

**Reviewer's code:** 02537284

**Reviewer's country:** Venezuela

**Science editor:** Jin-Lei Wang

**Date sent for review:** 2018-06-10

**Date reviewed:** 2018-07-04

**Review time:** 23 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

In their work, Lin et al. presented an analysis of the influence of CYP2C19 and IL-1B (-511) gene polymorphisms on the eradication of *Helicobacter pylori* by the use of hybrid therapy based on rabeprazole. They included a relatively low number of patients infected with *H. pylori* and observed an eradication rate of 92.94%. They found no

significant influence of the analyzed gene polymorphisms, which are expected to determine the rate of hepatic metabolism of rabeprazole and the level of gastric acid secretion, respectively, in the eradication of *Helicobacter pylori* by the use of hybrid therapy based on rabeprazole. In my opinion this work could be suitable to be accepted for publication in World Journal of Gastroenterology after address some minor considerations: 1) Authors must specify that they analyzed the interleukin 1-beta (IL-1B) -511 gene polymorphism. That is, IL-1 is a family or group of cytokines and IL-1B is one of its members. 2) In Abstract, where it says "cytochrome P450 2C", it should say "cytochrome P450 2C19". 3) In introduction, authors could comment how the level of acid secretion can affect *H. pylori* eradication. 4) Results (subheading: Factors associated with eradication of *H. pylori*): authors should not consider the T allele of IL-1B -511 polymorphism as mutation. It should be used the term allele or genotype when refer to the combination of two alleles. 5) Table 2: it should show CYP2C19 as heading in the respective column.

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

### *BPG Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA

**Telephone:** +1-925-223-8242

**Fax:** +1-925-223-8243

**E-mail:** bpgoffice@wjgnet.com

**https://** [www.wjgnet.com](http://www.wjgnet.com)

[ Y ] No